CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Arcus Biosciences, Inc.

RCUS
$3.06B
Mid Cap
NYSEPharmaceutical Preparations🇺🇸North AmericaHAYWARD627 employees

Drugs in Pipeline

7

Phase 3 Programs

5

Upcoming Catalysts

5

Next Catalyst

Aug 5, 2026

8d

Market Overview

Stock performance and key metrics

RCUS News
Catalyst Timeline

5 upcoming, 0 past

EarningsNext

RCUS Earnings Report

Aug 5, 2026

EPS Est: $-1.01 | FQ end 2026-06 | Call: 2026-08-05 15:00:00

4 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

How RCUS's past catalysts played out

Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Arcus Biosciences, Inc.'s drug pipeline?

CatalystAlert tracks 7 drug candidates in Arcus Biosciences, Inc.'s (RCUS) pipeline across Phase 3, Phase 2. Its lead program is Zimberelimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Arcus Biosciences, Inc.'s next FDA catalyst?

Arcus Biosciences, Inc.'s (RCUS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track RCUS biotech catalysts?

Add RCUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arcus Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply